Mechanisms underlying the anti-Helicobacter pylori effects of Lactobacilli secretomes

世界上65%的胃溃疡和癌症是由幽门螺杆菌引起的。抗生素治疗有严重的副作用，而且经常因为细菌耐药性而失败。在全球范围内，30%的加拿大人患有胃癌，人口老龄化使得几十年来更多的胃癌发生。大约95%的土著居民被殖民，并遭受胃溃疡和治疗失败的高发生率。乳酸菌是一种天然存在于肠道中的细菌，被认为是具有益生菌活性的好细菌。由行业合作伙伴Lallemand Health Solutions开发的乳酸菌制剂改善了体内抗幽门螺杆菌治疗，在Creuzenet实验室进行的20种乳酸菌体外测试中，大多数乳酸菌释放出抗幽门螺杆菌分子。pylorieffects。然而，这些影响背后的机制尚不清楚。我们建议研究这些分子是如何工作的，测试它们针对幽门螺杆菌中存在的特定传感器的假设。了解它们的作用机制将填补重要的知识空白，并将通过真正的科学证据验证活性菌株，这在益生菌领域往往缺乏。这将使我们的工业合作伙伴受益，他们有一个建立良好的传统，用强有力的科学数据支持所有功效声明。此外，我们的工作将有助于鉴定用于特定目的的最佳乳酸杆菌，并促进鉴定有益的抗h。幽门螺杆菌分子，可用于纯化形式，以增强混合配方中的活益生菌或提高目前抗生素治疗的疗效。这些对幽门螺杆菌感染患者和工业合作伙伴都有直接的好处，可以探索潜在的重要市场。此外，了解幽门螺杆菌和乳酸杆菌之间发生的分子相互作用可以作为其他复杂细菌相互作用的模型系统。这可能会产生扩展到其他领域的应用，如营养、生物技术甚至生物修复。

The bacterium Helicobacter pylori causes 65% of gastric ulcers and cancers worldwide. Antibiotic treatmentshave serious side effects and often fail because of bacterial resistance. Globally 30% of Canadians arecolonized and the aging of the population allows more gastric cancers to develop over decades. About 95% ofAboriginals are colonized and suffer from high rates of gastric ulcers and treatment failure. Lactobacilli arebacteria naturally present in the gut that are known as good bacteria with probiotic activity. Lactobacilliformulations developed by industry partner Lallemand Health Solutions improve anti- H. pylori treatments invivo and most of the 20 Lactobacilli tested in vitro in the Creuzenet lab released molecules with anti-H. pylorieffects. However, the mechanisms underlying those effects are not understood.We propose to examine how these molecules work, testing the hypothesis that they target specific sensorspresent in H. pylori. Understanding their mechanism of action will fill an important knowledge gap and willalso provide validation of active strains by bona fide scientific evidence, which is often lacking in the probioticfield. This will benefit our industrial partner who has a well-established tradition of backing all efficacy claimsby strong scientific data.Also, our work will help identify the best Lactobacilli to be used for specific purposes and facilitate theidentification of the beneficial anti-H. pylori molecules, which could be used in purified form to potentiate liveprobiotics in mixed formulations or to enhance the efficacy of current antibiotic treatments. These are directbenefits to the H. pylori-infected patients and the industrial partner who can explore a potentially significantmarket.Furthermore, understanding the molecular interactions that occur between H. pylori and Lactobacilli couldserve as a model system for other complex bacterial interactions. This could yield applications extending toother fields, such as nutrition, biotechnology or even bioremediation.